BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17847177)

  • 21. Antibiotic cost-containment.
    Huckleberry SD
    Drug Intell Clin Pharm; 1986; 20(7-8):589-91. PubMed ID: 3743415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
    Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
    Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic evaluation of antibiotic therapy: relevance to urinary tract infection.
    MacDonald TM
    J Antimicrob Chemother; 1994 May; 33 Suppl A():137-45. PubMed ID: 7928831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to improve pharmacoeconomic data generalisability between different countries.
    Li SC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1409-13. PubMed ID: 17661723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2007 Apr; 8(5):633-48. PubMed ID: 17376018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formulary management.
    Scroccaro G
    Pharmacotherapy; 2000 Oct; 20(10 Pt 2):317S-321S. PubMed ID: 11034059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia.
    Paladino JA
    Can J Hosp Pharm; 1995 Oct; 48(5):276-83. PubMed ID: 10152782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of therapeutic drug monitoring in pharmacoeconomics.
    Destache CJ
    Ther Drug Monit; 1993 Dec; 15(6):608-10. PubMed ID: 8122303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic formulary selection.
    Crowe HM; Quintiliani R
    Med Clin North Am; 1995 May; 79(3):463-76. PubMed ID: 7752722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approaches to drug therapy, formulary, and pathway management in a large community hospital.
    Halley HJ
    Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S17-21. PubMed ID: 11098316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic factors in the treatment of acute hypertension.
    Shulkin DJ
    Hosp Formul; 1994 Aug; 29 Suppl 2():S15-20. PubMed ID: 10135742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial formulary control: is the glass half empty or half full?
    Rapp RP; Pomeroy C
    Am J Health Syst Pharm; 1996 Sep; 53(17):2091-2. PubMed ID: 8870900
    [No Abstract]   [Full Text] [Related]  

  • 35. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures.
    Rifenburg RP; Paladino JA; Hanson SC; Tuttle JA; Schentag JJ
    Am J Health Syst Pharm; 1996 Sep; 53(17):2054-62. PubMed ID: 8870892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibiotic therapy of hospital-acquired pneumonia and its pharmacoeconomics].
    Kolář M; Htoutou Sedláková M; Urbánek K; Uvízl R; Adamus M; Imwensi OP
    Klin Mikrobiol Infekc Lek; 2016 Mar; 22(1):4-12. PubMed ID: 27476589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transitional (intravenous to oral) antibiotic therapy.
    Quintiliani R; Grant E; Quintiliani R
    J Med Liban; 2000; 48(4):233-40. PubMed ID: 11214195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antibacterial therapy: pharmacoeconomic aspects].
    Popova IuN; Belousov DIu; Omel'ianovskiĭ VV
    Antibiot Khimioter; 2002; 47(9):24-30. PubMed ID: 12619518
    [No Abstract]   [Full Text] [Related]  

  • 39. Formulary control of antimicrobial usage. What price freedom?
    Dunagan WC; Medoff G
    Diagn Microbiol Infect Dis; 1993; 16(3):265-74. PubMed ID: 8477583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.